SciSparc Ltd. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
SPRC Nasdaq 2830 scisparc.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for SciSparc Ltd.

NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-Its-Kind Treatment for Tourette Syndrome - Aug 5th, 2026 6:48 am
SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome - Aug 5th, 2026 6:22 am
SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics - Jul 31st, 2026 6:20 am
SciSparc Advances Quantum Clinical Data Analytics as NeuroThera Validates Proprietary Computing Platform - Jul 29th, 2026 8:30 am
SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company - Jul 29th, 2026 6:32 am
SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity - Jul 27th, 2026 6:25 am
NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome - Jul 15th, 2026 7:27 am
SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome - Jul 15th, 2026 6:41 am
SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum - Jun 4th, 2026 5:32 am
NeuroThera Labs Inc. Announces Closing of Acquisition of Majority Stake in CliniQuantum Ltd. - Jun 3rd, 2026 4:04 pm
SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum - May 28th, 2026 6:40 am
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy - Mar 16th, 2026 6:20 am
NeuroThera Labs - Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy - Mar 16th, 2026 5:30 am
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy - Mar 13th, 2026 5:45 am
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - Mar 12th, 2026 5:55 am
NeuroThera Labs Announces Publication of International Patent in Collaboration With Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - Mar 11th, 2026 5:30 am
SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails - Mar 10th, 2026 7:28 am
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - Mar 10th, 2026 6:59 am
Neurothera Labs Inc. Announces Definitive Agreement to Acquire Majority Stake in Cliniquantum Ltd. - Mar 10th, 2026 5:30 am
SciSparc announces 1-for-9 reverse share split - Mar 3rd, 2026 6:23 am